The Association Between Co-morbidity and Mortality After Abdominal Aortic Aneurysm Endografting in Patients Ineligible for Elective Open Surgery  by Riambau, V et al.
Eur J Vasc Endovasc Surg 22, 265–270 (2001)
doi:10.1053/ejvs.2001.1443, available online at http://www.idealibrary.com on
The Association Between Co-morbidity and Mortality After
Abdominal Aortic Aneurysm Endografting in Patients
Ineligible for Elective Open Surgery
V. Riambau∗1, R. J. F. Laheij2, C. Garcı´a-Madrid1 and G. Sa´nchez-Espin1 on behalf of
the EUROSTAR group
1Section of Vascular Surgery, Hospital Clı´nic, Barcelona, Spain, 2Department of Vascular Surgery,
Catharina Hospital, Eindhoven, The Netherlands
Objective: to investigate whether co-morbidity affects mortality after endovascular stenting in patients who are fit and
unfit for open surgery.
Methods: data were obtained from the EUROSTAR registry. The association between co-morbidity and mortality was
examined by Cox proportional hazards models.
Results: between 1994 and July 2000, 2862 patients underwent aneurysm stenting; 381 were unfit for open surgery.
The early/late mortality rates for patients fit for surgery, patients unfit for surgery and patients unfit for anaesthesia
were 2.7/5.2%, 5.1/11.4% (p=0.035/p<0.0001) and 3.7/11.0% (NS/p=0.016), respectively. The survival curves among
patients with poor medical condition were significantly worse than in those patients with a good medical condition (p=
0.001). The presence or absence of co-existing diseases did not affect the mortality rate in patients unfit for open surgery.
The age-adjusted mortality risks of patients fit for open surgery and pulmonary disease or diabetes mellitus were 1.41
(1.02–1.95) and 1.75 (1.12–2.74), respectively.
Conclusions: patients with co-morbidity had a significantly higher mortality after aortic endografting compared with
patients fit for open surgery. Co-morbidity did not increase mortality after endovascular abdominal repair in patients
unfit for open surgery. Endovascular repair of abdominal aortic aneurysm seems to have a limited benefit in patients
unfit for open surgery.
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Introduction Methods
Identification of asymptomatic abdominal aortic an- Patients
eurysms (AAA) may reduce the risk of death from
rupture by providing the opportunity for elective re- This study was part of the European collaborators
pair.1,2 However, a significant proportion of patients with on stent-graft techniques for abdominal aortic
AAA has co-morbidity which makes them unfit for an aneurysm repair (EUROSTAR) study.7 The cohort
open surgery. Stenting of AAA may be an alternative in consists of patients treated in a large number of
such patients.3–5 However, even the risk of endovascular European vascular institutions. All patients received
repair in these patients might exceed that of non- information about this registry and consented to
operative management.5 The aim of the present study have their data included in the study. Patients op-
was to investigate whether co-morbidity affects mor- erated before July 1996 were included in the retro-
tality in patients fit and unfit for open surgery. spective part of the study, and after this date patients
were included prospectively. During the prospective
study period, the planned procedure was registered
∗ Please address all correspondence to: V. Riambau, Section of at the data registry centre before endovascular treat-Vascular Surgery, Institute of Cardiovascular Diseases, Hospital
Clı´nic. Villarroel, 170, 08036 Barcelona, Spain. ment.
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Table 1. Baseline characteristics of patients fit for an open procedure or anaesthesia, those unfit for
an open procedure, and those unfit for anaesthesia.
Characteristic Normal Unfit for open Unfit for p value
condition procedure anaesthesia
(n=2481) (n=272) (n=109)
Age 0.001
Younger than 65 years 600 (24.2) 58 (21.3) 15 (13.8)
65 till 75 years 1157 (46.6) 113 (41.5) 44 (40.3)
Older as 75 years 724 (29.2) 101 (37.2) 50 (45.9)
Sex 0.67
Male 2286 (92.1) 251 (92.3) 103 (94.5)
Female 195 (7.9) 21 (7.7) 6 (5.5)
Current smoking 1226 (54.5) 161 (62.2) 74 (68.5) 0.002
Hypertension 1345 (59.3) 170 (64.6) 65 (60.8) 0.24
Diabetes mellitus 218 (9.7) 34 (13.1) 15 (14.2) 0.08
Pulmonary disease 782 (35.0) 151 (60.2) 82 (76.6) 0.001
Cardiovascular disease 1283 (56.7) 206 (77.4) 85 (78.7) 0.001
Carotid disease 350 (15.7) 66 (25.5) 26 (25.2) 0.001
Renal insufficiency 328 (14.9) 90 (34.8) 32 (30.2) 0.001
Hyperlipaemia 822 (37.6) 103 (41.2) 50 (49.0) 0.05
Type of device 0.001
AneuRx 636 (25.6) 55 (20.2) 16 (14.7)
EVT 111 (4.5) 12 (4.4) 4 (3.7)
Excluder 116 (4.7) 14 (5.2) 7 (6.4)
Stentor 290 (11.7) 17 (6.3) 3 (2.8)
Talent 323 (13.0) 47 (17.3) 13 (11.9)
Vanguard 751 (30.3) 90 (33.1) 51 (46.8)
Zenith 198 (8.0) 31 (11.4) 10 (9.2)
Percentages in parentheses.
Examinations Data analysis
Information was obtained before and during the pro- Chi-square analysis was used to compare the baseline
characteristics of the subjects. Patients fit for opencedure, predischarge, 1, 3, 6, 12, 18, 24 months and
subsequently yearly. The initial examination included surgery or general anaesthesia were considered to be
in good medical condition. Patients unfit for opena medical history, physical examination, contrast en-
hanced computed tomography and angiography. The surgery or general anaesthesia were considered to
be in poor medical condition. Survival analysis wasoverall general medical condition of the patient was
determined by the surgeon/anaesthesiologist at the calculated by Kaplan–Meier testing.9 In order to assess
the association between health status and clinical out-different centres was characterised by specific data
entry points on the case report forms as: fit for open come, we calculated age-adjusted mortality rates.9,10
To quantify the correlation between mortality, co-mor-surgery, unfit for open surgery and unfit for general
anaesthesia. Patients unfit for open surgery and/or bidity and health status a univariate and multivariate
regression analysis based on Cox proportional hazardsunfit for anaesthesia were considered as patients in-
eligible for elective open repair due to the poor medical models was constructed. The exact Fisher’s test was
applied in order to know the correlation between theconditions. Also, co-existing diseases (diabetes mel-
litus, hypertension, hyperlipemia, cardiac status, ca- previous medical condition at entry and the cause of
death.9,10 Statistical analysis was performed with SASrotid disease, renal status, and pulmonary status) were
reported according to the SVS-ISCV risk score.8 The software.
operative data included information about the pro-
cedure, type of endograft used and complications. Results
Treatment results were assessed by clinical ex-
amination and by imaging studies of the vascular Baseline characteristics
morphology and endograft during follow-up. In case
of death, details of this event were recorded as they Between January 1994 and August 1998, 2862 patients
in 88 participating hospitals underwent endoluminaloccurred.
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Table 2. Baseline aneurysm morphology of patients fit for an open procedure or anaesthesia, those
unfit for an open procedure, and those unfit for anaesthesia.
AAA Morphology Normal Unfit for open Unfit for p value∗
condition procedure anaesthesia
D2 22.4±2.8 22.6±3.5 22.5±3.1 0.61
D3 55.6±10.7 59.6±11.9 60.5±14.3 0.001
H1 27.4±11.6 27.4±11.9 27.9±11.1 0.89
D2: Proximal neck diameter; D3: Aneurysm sac diameter; H1: Proximal neck length.
Values: mean±standard deviation (mm). ∗Chi-square test.
abdominal aortic aneurysm repair. A total of 381 (13%) The 1-year cumulative survival rates of patients fit and
unfit for open surgery were 93% and 83%, respectivelypatients were ineligible for open repair; 272 were unfit
for surgery, 109 were unfit for general anaesthesia. (Fig. 1). The survival in patients unfit for surgery or
anaesthesia was significantly worse (p=0.001).Patients in a poor medical condition were older and
more often had cardiac disease, chronic obstructive
pulmonary disease, and renal insufficiency (Table 1).
The Vanguard device was used more often in high-risk
Co-morbiditypatients. Aneurysm diameter was greater for patients
unfit for open surgery and/or anaesthesia (Table 2).
Co-existing diseases were reported in 2176 (90%)
patients, 1671 (69%) had more than two diseases.
These included diabetes mellitus, hypertension, hyper-
Survival lipaemia, cardiac disease, carotid disease, renal in-
sufficiency, and pulmonary disease in 267 (10%), 1580
The early/late mortality rates for patients fit for sur- (60%), 975 (39%), 1574 (60%), 442 (17%), 450 (18%),
gery, patients unfit for open surgery and patients unfit and 1015 (39%) patients, respectively. There were no
for anaesthesia were 2.7/5.2%, 5.1/11.4% (p=0.035/ statistical differences in mortality between the absence
p<0.0001) and 3.7/11.0% (NS/p=0.016), respectively. and presence of co-existing diseases in patients with
The number of deaths during the entire follow-up for poor medical condition. In contrast, results from re-
patients in good medical condition and those unfit for gression models revealed a difference in mortality after
open surgery and those unfit for general anaesthesia
were 196, 45 and 16, respectively. The commonest
causes of death were cardiovascular disease, pul-
monary disease, malignancy and unknown (Table 3).
Table 3. Main causes of death during follow-up for patients fit
for an open procedure or anaesthesia, those unfit for an open
procedure, and those unfit for anaesthesia.
Main cause of death Normal Unfit for open Unfit for
condition procedure anaesthesia
Cardiac 58 19 4
Pulmonary 11 5 2
Cancer 42 6 4
Stroke 12 3 2
Sepsis 5 3 1
Multiorgan failure 2 1 1
AAA rupture 8 1 0
Accident 2 1 0
Suicide 0 1 0
Renal failure 3 1 0
Vascular complications 8 1 0
Gastro-intestinal 7 0 0
complications
Stent related 7 0 0
Cirrhosis 1 0 0
Haematologic disorder 2 0 0
Unknown 28 3 2 Fig. 1. Survival of the patients fit for an open procedure or an-
aesthesia (––), those unfit for an open procedure (–––), and thoseTotal 196 45 16
unfit for anaesthesia (–·–·). Log rank test p<0.001.
Eur J Vasc Endovasc Surg Vol 22, September 2001
V. Riambau et al.268
Table 4. Rates and relative risk of death among patients considered Table 5. Overall mortality rates classified according to SVS/ISCVS
risk score.fit for an open procedure or anaesthesia and those considered
unfit for an open procedure or anaesthesia, by co-morbidity at
baseline. Associated diseases Mortality rates for SVS/ p value∗
ISCVS risk score
Patients fit for open Patients unfit for
surgery open surgery 0 1 2 3
No. of Mortality No. of Mortality Diabetes mellitus 8.5 11.9 19.6 33.3 0.007
Smoking 8.8 9.8 8.8 9.4 0.9patients rate patients rate
Hypertension 8.4 9.0 9.5 8.3 0.8
Hyperlipaemia 9.8 9.4 4.3 5.16 0.04Hyperlipaemia
Absent at entry 1362 9.18 199 14.57 Cardiac disease 7.8 6.7 11.5 24.8 0.001
Carotid disease 8.8 9.2 8.9 18.4 0.13Prevalent at 822 6.20 127 16.99
entry Renal disease 8.1 12.1 13.7 10.7 0.04
Pulmonary disease 7.8 10.6 9.8 14.8 0.03Age-adjusted 0.78 (0.6–1.1) 1.25 (0.7–2.1)
relative risk
(95% C.I.) ∗Chi-square test.
Cardiac disease
Absent at entry 980 7.35 83 13.25
Table 6. Matching between main cause of death during follow-Prevalent at 1283 8.42 291 16.84
up and main medical cause to consider unfit for open surgery inentry
patients unfit for an open procedure, and those unfit for an-Age-adjusted 1.07 (0.8–1.4) 1.14 (0.6–2.2)
aesthesia.relative risk
(95% C.I.)
Medical condition Unfit for open Unfit for general
Renal insufficiency surgery anaesthesia
Absent at entry 1870 7.49 243 12.76
Prevalent at 328 9.76 122 18.85 At As cause At As cause
entry entry of death entry of death
Age-adjusted 1.41 (1.0–2.1) 1.59 (0.9–2.8)
relative risk Cardiac 26 16∗ 4 3
(95% C.I.) Pulmonary 3 2 3 0
Renal 3 1 1 0Pulmonary disease
Cancer 7 3 0 0Absent at entry 1453 7.30 125 14.40
Poor general 1 – 3 –Prevalent at 782 9.34 233 15.45
conditionentry
Previous 5 – 1 –Age-adjusted 1.40 (1.0–1.9) 1.29 (0.7–2.3)
laparotomyrelative risk
Not available 0 – 4 –(95% C.I.)
Total 45 16Diabetes mellitus
Absent at entry 2042 7.64 316 14.24
∗Chi-square; p-value=0.002.Prevalent at 218 11.93 49 20.41
entry
Age-adjusted 1.66 (1.1–2.5)∗ 1.42 (0.7–2.8)
relative risk the cardiac status at entry had a significant correlation
(95% C.I.) with the cause of death in the patients unfit for open
surgery (p=0.002).∗ p-value <0.05.
aneurysm stenting between the absence or presence of
diabetes mellitus, renal disease, or pulmonary disease Discussion
at entry in patients in a good medical condition (Table
4). The age-adjusted mortality risks (95% confidence Patients unfit for open surgery have a significantly
higher mortality after endovascular abdominal aorticinterval) of patients with an otherwise good medical
condition and pulmonary disease or diabetes mellitus aneurysm repair compared to those who are con-
sidered fit for open surgery. Almost all patients hadwere 1.40 (1.0–1.9) and 1.66 (1.1–2.5), respectively.
Overall mortality rates correlated with the severity co-existing diseases independly whether or not the
patient had a good or bad medical condition. However,of the degree of some co-morbidities like diabetes
mellitus, cardiac risk, renal and pulmonary diseases none of the investigated co-existing diseases affected
mortality after endovascular repair in patients con-(Table 5). Moreover, we observed a weak positive
correlation when overall medical conditions to con- sidered unfit for open surgery. On the other hand,
patients with an otherwise good medical conditionsider unfit patients and the same conditions as the
main cause of death in patients unfit for open surgery and diabetes mellitus at entry were 1.66 times (95%
CI; 1.1–2.5) more likely to die than a patient withoutand general anaesthesia were matched (Table 6). Only
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diabetes mellitus. Furthermore, patients with pul- elective open repair. Our results indicate that patients
unfit for an open procedure or unfit for general an-monary disease at entry and in another good medical
aesthesia have an increased risk of systemic com-condition were 1.40 times (95% CI; 1.0–1.9) more likely
plications and of death. Almost 20% of these patientsto die than a patient without pulmonary disease. The
died within the first year from causes unrelated togeneral medical condition that led us to classify a
their aneurysm not benefiting from their aneurysmparticular patient as unfit for open surgery or general
repair.anaesthesia seems to be more sensitive than SVS/ISCV
From EUROSTAR substudies we identified somerisk score in order to predict mortality in patients
clinical and anatomical risk factors.13,14 These data andwho must be undergone to endovascular repair of
the results from the present study, the results fromabdominal aortic aneurysm. Perhaps, beyond the SVS/
ongoing randomised trials and the new device im-ISCV risk score other parameters like age, silent cardio-
provements, will contribute to understand the naturalvascular disease, obesity, previous laparotomy or can-
history of the aortic endografting and to select muchcer history, could also be important in order to predict
better our patients.survival. Therefore, it seems that the additional effect
In conclusion, patients with poor medical conditionof endovascular treatment increases mortality espe-
have a significantly higher mortality after abdominalcially in patients with a poor medical condition. In
aortic aneurysm endografting compared with patientsother words, the risk of endovascular repair in patients
fit for open surgery. But none of the investigated co-with co-existing diseases which makes them unfit
existing diseases affected mortality in patients unfitfor elective open abdominal aortic aneurysm surgery
for surgery or anaesthesia. Patients with good medicalseems to exceed that of the mortality rate related to
condition and diabetes or pulmonary disease at entrythe natural history of abdominal aortic aneurysm lar-
had higher mortality rate. In consequence, endo-ger than 5 cm in diameter.11 Whether this finding was
vascular repair of abdominal aortic aneurysm seemsan additional effect of treatment or the result of the
to have a limited benefit in patients ineligible for opennatural course of co-morbidity is, however, unclear.
surgery.Nevertheless, one important limitation of this study
While we await randomized controlled data, theis the lack of a control group of patients with abdominal
decision to endograft a patient’s ineligible for openaortic aneurysm and classified as ineligible for open
surgery remains difficult.surgery and treated by observation and medical treat-
ment. But this kind of study exceeds the aim and
protocol of EUROSTAR. For this particular purpose
we should wait for more information derived from Acknowledgements
some randomized studies like EVAR-2 trial.12
This study investigated whether co-existing diseases The authors acknowledge the EUROSTAR Collaborators who con-
tributed to this study: Austria: Prof. G. Kretschmer, Vienna; Belgium:affected mortality after endovascular stenting between
Dr J. Bleyn, Berchem; Dr H. Massin, Giily; Prof. A. Nevelsteen,patients fit and unfit for open surgery. The overall Leuven; Dr M. Possiers, Bonheiden; Dr P. Stabel, Turnhout; Dr F.
general medical condition of patients is an important van Elst, St Tmiden; France: Dr B. Age, Lyon; Dr C. Amicabile,
Nancy; Prof. J. P. Becquemin, Paris Cre´teil; Dr Cardon, Nimes; Prof.predictor of survivorship after endovascular ab-
J. P. Favre, St Etienne; Prof. J. C. Gaux, Paris cedex; Dr C. Giraud,dominal aortic aneurysm repair. Patients with ab- Toulouse cedex; Prof. P. Kreitmann, St Laurant du Var; Dr Magne,
dominal aortic aneurysms may be deemed inoperable Grenoble; Prof. Marty-Ane, Montpellier; Dr J. Marzella, Nanterre;
Dr Meaulle, Grenoble cedex; Dr C. Mialhe, Draguignan; Dr Piquet,due to the presence of co-morbidity that led us to
Marseille; Prof. H. Rousseau, Toulouse; Dr M. A. Vasseur; Lilleclassify as an ineligible patient for open surgery. But Cedex; Germany: Prof. J. Allenberg, Heidelberg; Prof. M. Betzler,
Essen-Ruttenscheid; Dr Blum, Freiberg; Dr F. Johnsen, Hamburg;this is a subjective parameter. Therefore, it is so difficult
Dr Med. Kasprzak, Regensburg; Prof. I. Klempa, Bremen; Dr R.to identify high risk patients who can benefit from
Kolvenbach, Dusseldorf; Prof. P. C. Maurer, Munchen; Dr Pamler,
endovascular treatment. On the other hand, it is also Ulm; Prof. W. Stelter, Frankfurt; Dr A. Viehofer, Bonn; Dr C. von
Duber, Mainz; Dr. G. Voshage, Hanover; Dr R. Wickenhofer, Koblenz;difficult to accurately predict aneurysm rupture and
Greece: Prof. P. Balas, Psihico Athens; Ireland: Prof. Shanik, Dublin;life expectancy in patients with serious co-morbidities. Israel: Prof. B. Morach, Tel Aviv; Dr D. Orron, Tel Aviv; Italy: Prof.
Maybe the presence of symptoms and the technical P. Cao, Perugia; Dr G. Coppi, Modena; Luxembourg: Dr Berg,
Luxembourg; The Netherlands: Dr R. Balm, Amsterdam; Dr W. B.and anatomical ease could help us in our decision
Barendrecht, Nijmegen; Dr M. H. M. Bender, Veldhoven; Dr J. Buth,process, but always it will be an individual choice Eindhoven; Dr J. C. A. de Mol van Otterloo, Den Haag: Dr A. de
with ethical implications. Smet, Rotterdam; Dr W. R. de Vries, Amhem; Dr H. R. Dop,
Groningen; Prof. B. Eikelboom, Utrecht; Dr R. H. Geelkerken, En-Also, in this paper we have attempted to assess
schede; Dr Hamming, Tilburg; Dr P. Jo¨rning, Zwolle; Dr S. Kranen-outcome after endoluminal abdominal aortic an- donk, Tilburg; Dr F. Moll, Nieuwegein; Dr G. W. H. Schurink,
Maastricht; Prof. J. H. van Bockel, Leiden; Prof. A. C. van der Ham,eurysm repair in 381 patients considered unfit for an
Eur J Vasc Endovasc Surg Vol 22, September 2001
V. Riambau et al.270
PM Rotterdam; Dr J. G. J. M. van Iersel, Doetinchem; Dr H. van 5 Chuter TA, Reilly LM, Faruqi RM et al. Endovascular an-
eurysm repair in high risk patients. J Vasc Surg 2000; 31: 122–133.Overhagen, Den Haag; Dr van Sambeek, Rotterdam; Prof. J. van
6 Lajeij RJF, Marrewijk CJ van, on behalf of the EUROSTARVliet, Nijmegen; Dr E. Verhoeven, Groningen; Dr W. Wisselink,
group. Endovascular stenting of abdominal aortic aneurysm inAmsterdam; Norway: Prof. A. Kroeze, Oslo; Prof. K. Kvemebo,
patients unfit for elective open surgery. Lancet 2000; 356: 832.Oslo; Prof. H. Myhre, Trondhheim; Poland: Prof. Michalak, Lublin;
7 Harris PL, Buth J, Mialhe C, Myhre HO, Norgen L. The needSpain: Dr E. Criado, Madrid; Dr M. de Blas, Donostia San Sebastian;
for clinical trials of endovascular abdominal aortic aneurysmDr L. Ferna´ndez Alonso, Pamplona; Dr R. Ferna´ndez-Samos, Leo´n;
stent-graft repair: the EUROSTAR-project. J Endovasc Surg 1997;Dr J. R. Pulpeiro, Lugo; Dr Sa´nchez Corral, Madrid; Dr D. Tagarro,
4: 72–77.Madrid; Sweden: Dr H. Jansson, Orebro; Prof. L. Norgen, Lund; Dr
8 Rutherford RB, Flanigan DP, Gupta SK et al. SuggestedJ. Swedenborg, Stockholm; Switzerland: Dr A. Enzler, Zurich; United
standards for reports dealing with lower limb ischemia. J VascKingdom: Dr G. Abbott, Chester; Dr R. Asleigh, Manchester; Dr R.
Surg 1986; 4: 80–94.Baird, Bristol; Mr S. Darke, Bournemouth; Dr R. Edwards, Glasgow;
9 Rothman KJ. Modern Epidemiology. USA: Little, Brown andDr D. Ettler, Hull; Peter D. Harris, Liverpool; Dr J. Wolfe, London;
Company, 1986.Dr M. Wyatt, Newcastle-upon-Tyne.
10 Piantadosi S. Clinical trials: a methodologic perspective. Canada:
John Wiley & Sons, 1997.
11 Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal
aortic aneurysm. A population-based study. N Engl J Med 1989;
321: 1009–1014.
12 Greenhalgh RM, Brown LC, Powell JT. The UK EndoVascular
Aneurysm Repair (EVAR) trials: background and methodology.References
In: Greenhalgh RM, Powell JT, Mitchell AW, eds. Vascular and
Endovascular Opportunities. London: WB Saunders, 2000: 215–227.
1 Vliet JA van der, Boll APM. Abdominal aortic aneurysm. 13 Buth J, Laheij RJF, EUROSTAR Collaborators. Early com-
Lancet 1997; 349: 863–866. plications and endoleaks after endovascular abdominal aortic
2 Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328: aneurysm repair: Repport of a multicenter study. J Vasc Surg
1167–1172. 2000; 31: 134–146.
3 Parodi JC, Palmaz JC, Barone HD. Traitement des ane´vrysmes 14 Harris PL, Vallabhaneni R, Desgranges P et al. for the
de l’aorte abdominale par prothe`se endoluminale mise en place EUROSTAR Collaborators. Incidence and risk factors of late
par voie fe´morale. Ann Chir Vasc 1991; 5: 491–499. rupture, conversion, and death after endovascular repair of
4 Woodburn KR, May J, White GH. Endoluminal abdominal infrarenal aortic aneurysm: The EUROSTAR experience. J Vasc
Surg 2000; 32: 739–749.aortic aneurysm surgery. Br J Surg 1998; 85: 435–443.
Eur J Vasc Endovasc Surg Vol 22, September 2001
